Atopic dermatitis (AD) is a very common, heterogeneous and debilitating disease with a need for new treatment optionsCAN10 targets several pathways relevant for AD but distinct from current treatments ...

Inflammation and mitochondrial function as mechanisms in accelerated aging (AA) across substance use disorders (SUDs). This ...

Scientists have uncovered a surprising trick used by the herpes simplex virus to wake up inside the body. Researchers at the ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) will present new data from studies evaluating two of its internally developed, ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

Bergen, Norway, April 23, 2025 – Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that it has raised NOK62 ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or ...

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular ...

Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the U.S. Food and Drug Administration (FDA) has ...

Clinical findings show association between nadunolimab and lower incidence and later onset of CIPNPreclinical data show prevention of both chemotherapy- and antibody-drug ...